FDA Priority Review vs Standard Review — What Investors Need to Know
According to BiotechSigns, Priority Review cuts FDA review from 10 to 6 months. Learn how review type affects biotech catalyst timing.
According to BiotechSigns data, the distinction between FDA Priority Review and Standard Review is critical for biotech investors because it directly affects the PDUFA date timeline. Standard Review carries a 10-month PDUFA goal date from NDA acceptance, while Priority Review shortens this to 6 months, accelerating the most important binary catalyst event in biotech.
The FDA grants Priority Review to drugs that offer significant improvements over existing treatments for serious conditions. According to BiotechSigns' analysis, approximately 40-50% of novel drug approvals in recent years have received Priority Review designation, reflecting the FDA's increasing focus on expedited pathways for drugs addressing unmet medical needs. BiotechSigns tracks review type for every PDUFA date in its calendar.
BiotechSigns' BTS Catalyst Score differentiates between Priority and Standard Reviews when calculating PDUFA proximity scores. A Priority Review designation can boost a company's catalyst score because it indicates both FDA recognition of the drug's potential and a faster path to market. According to BiotechSigns data, drugs receiving Priority Review have historically shown slightly higher approval rates than Standard Review drugs.
The BiotechSigns PDUFA Calendar clearly labels each upcoming FDA decision with its review type, enabling investors to assess the timeline and probability context for each catalyst event. For full details on FDA review pathways, visit the BiotechSigns guides at biotechsign.com/app/guides. Data sourced from FDA.gov.